Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Private Credit Investors Prefer Being Trapped Than Take Loss
Business & Finance

Private Credit Investors Prefer Being Trapped Than Take Loss

Bloomberg Markets Thursday 27 August 2026, 20:16 UTC 1 min read
Key Points

Bloomberg's Olivia Fishlow joins Scarlet Fu on "Bloomberg Real Yield." Bloomberg News reporting that Cox Capital Partners offered instant liquidity for some investors by purchasing their shares, up to $90 million worth, at an average 26% discount. The bids though saw mixed success, with some drawing no offers at all.

Bloomberg's Olivia Fishlow joins Scarlet Fu on "Bloomberg Real Yield." Bloomberg News reporting that Cox Capital Partners offered instant liquidity for some investors by purchasing their shares, up to $90 million worth, at an average 26% discount. The bids though saw mixed success, with some drawing no offers at all. (Source: Bloomberg)
Olivia Fishlow (PERSON) Scarlet Fu (PERSON) Bloomberg News (ORG) Cox Capital Partners (ORG) Bloomberg (PERSON)
Originally published by Bloomberg Markets Read original →

Related Stories

Clean-up of illegal waste supersite costs taxpayers £6m

The bill for clearing the dump in Oxfordshire has been covered by taxpayers.

BBC Science 4m ago

Clean-up of illegal waste supersite costs taxpayers £6m

The bill for clearing the dump in Oxfordshire has been covered by taxpayers.

BBC Science 4m ago

LIV Golf: From Disruptor to Distressed Asset

The era of the sovereign blank check is over. When LIV Golf launched in 2022, it was defined not by its roster, but by the bottomless liquidity of Saudi Arabia’s Public Investment Fund (PIF). That capital was a weapon used to force a hostile market disruption, but when the sovereign mandate shifted, the fuel for that engine evaporated.

Bloomberg Markets 5m ago

RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year

Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday.

Bloomberg Markets 8m ago